IN2014DN00254A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00254A
IN2014DN00254A IN254DEN2014A IN2014DN00254A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A IN 254DEN2014 A IN254DEN2014 A IN 254DEN2014A IN 2014DN00254 A IN2014DN00254 A IN 2014DN00254A
Authority
IN
India
Prior art keywords
compositions
treatment
invention include
include methods
adipose deposits
Prior art date
Application number
Other languages
English (en)
Inventor
Katherine Cernok
Kenneth Martinez
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014DN00254A publication Critical patent/IN2014DN00254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IN254DEN2014 2011-07-20 2012-07-19 IN2014DN00254A (instruction)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509700P 2011-07-20 2011-07-20
PCT/US2012/047405 WO2013013042A1 (en) 2011-07-20 2012-07-19 Botulinum toxins for use in a method for treatment of adipose deposits

Publications (1)

Publication Number Publication Date
IN2014DN00254A true IN2014DN00254A (instruction) 2015-06-05

Family

ID=46601917

Family Applications (1)

Application Number Title Priority Date Filing Date
IN254DEN2014 IN2014DN00254A (instruction) 2011-07-20 2012-07-19

Country Status (12)

Country Link
US (1) US20140127188A1 (instruction)
EP (1) EP2734224A1 (instruction)
JP (1) JP2014520892A (instruction)
KR (1) KR20140082956A (instruction)
CN (1) CN103702681A (instruction)
AU (1) AU2012283968B2 (instruction)
BR (1) BR112014001066A2 (instruction)
CA (1) CA2841955A1 (instruction)
IN (1) IN2014DN00254A (instruction)
MX (1) MX2014000612A (instruction)
RU (1) RU2014103543A (instruction)
WO (1) WO2013013042A1 (instruction)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9655926B1 (en) 2013-08-23 2017-05-23 Amiya Prasad Treatment for hair thinning and hair loss
US9884001B2 (en) * 2014-08-07 2018-02-06 Sang Duck Kim Botulinum toxin in aerosol form and method of facial contouring using the same
TWI757260B (zh) 2015-12-18 2022-03-11 中國大陸商南大光電半導體材料有限公司 參（二矽烷基）胺
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
CN110996979A (zh) * 2017-05-18 2020-04-10 雷文斯治疗公司 颈肌张力障碍的治疗方法
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT758900E (pt) 1994-05-09 2002-09-30 William J Binder Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DK1949909T3 (en) 1997-07-15 2014-03-24 Univ Colorado Regents Use of botulinum toksinterapi for the treatment of dysfunction of urge type
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
AU2003263860A1 (en) * 2002-08-19 2004-03-03 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US8404249B2 (en) * 2004-03-03 2013-03-26 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
BRPI0619134B8 (pt) * 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US20110177140A1 (en) * 2007-08-31 2011-07-21 Rainer Voegeli 4-amidino benzylamines for cosmetic and/or dermatological use
US20090297632A1 (en) * 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
SG10201608732VA (en) * 2008-06-26 2016-12-29 Anterios Inc Dermal delivery
RU2530629C2 (ru) * 2009-03-02 2014-10-10 Дорис ЭКСЕЛ Вызываемая медикаментозными средствами липоатрофия для косметических целей

Also Published As

Publication number Publication date
US20140127188A1 (en) 2014-05-08
JP2014520892A (ja) 2014-08-25
CN103702681A (zh) 2014-04-02
RU2014103543A (ru) 2015-08-27
MX2014000612A (es) 2014-02-27
EP2734224A1 (en) 2014-05-28
BR112014001066A2 (pt) 2017-02-21
KR20140082956A (ko) 2014-07-03
AU2012283968A1 (en) 2014-02-06
CA2841955A1 (en) 2013-01-24
WO2013013042A1 (en) 2013-01-24
AU2012283968B2 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
IN2015DN00127A (instruction)
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
GB201103062D0 (en) Method
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
PH12015500525A1 (en) Formulations of enzalutamide
IN2014CN04765A (instruction)
MX355728B (es) Inhibidores de cinasas.
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
MX355543B (es) Macrociclos peptidomiméticos.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2014CN03555A (instruction)
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MY157341A (en) Methods and compositions for treating lung cancer
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
PH12014501032A1 (en) 2-thiopyrimidinones
IN2014CN04634A (instruction)
IN2014DN00254A (instruction)
IN2014DN09450A (instruction)
IN2013MU00848A (instruction)
MX393754B (es) Metodos y composiciones para inhibir cnksr1
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
MX347541B (es) Analogos de acido sialico.